Table 3.

Demographics, clinical features, treatments, and laboratory findings of MS patients positive to SARS-CoV-2 IgG/IgM in May–June 2020.

	1	2	3	4	5	6	7	8	9
Age, years	39	54	42	27	35	65	38	57	29
Sex	Male	Female	Female	Female	Female	Female	Female	Male	Male
COVID-19 symptoms	None	Cough	None	None	None	None	None	None	Fever, anosmia
COVID-19 at-risk behaviour	None	None	None	None	None	None	None	None	Travel
EDSS	2.5	3.0	6.5	1.0	4.5	2.5	4.5	4.0	1.5
DMT	Alemtuzumab	Natalizumab	Alemtuzumab	Natalizumab	Natalizumab	Teriflunomide	Alemtuzumab	None	Cladribine
Last DMT administration	January 2019	February 2020	June 2018	March 2020	February 2020	Ongoing	January 2018		July 2019
Comorbidities	None	None	None	None	None	None	None	None	None
White blood cell count *, ×103/μL	10.27	7.56	7.45	6.93	5.6	7.17	7.29	3.25	4.12
Total lymphocyte count **, ×103/μL	1.81	2.85	0.90	3.18	3.06	1.97	1.61	0.69	0.71
Lactic dehydrogenase ***, U/L	274	225	215	178	190	332	172	239	186

* Normal range 4–10 × 10³/μL; ** Normal range 1–4.8 × 10³/μL; *** Normal range 140–280 U/L.